Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;20(1):76-82.
doi: 10.1007/s12663-019-01278-x. Epub 2019 Aug 30.

Management of Large Oroantral Fistulas Caused by Medication-Related Osteonecrosis with the Combined Sequestrectomy, Buccal Fat Pad Flap and Platelet-Rich Fibrin

Alparslan Esen  1 , Sebnem Akkulah  1
Affiliations

Management of Large Oroantral Fistulas Caused by Medication-Related Osteonecrosis with the Combined Sequestrectomy, Buccal Fat Pad Flap and Platelet-Rich Fibrin

Alparslan Esen et al. J Maxillofac Oral Surg. 2021 Mar.

Abstract

Purpose: The aim of this retrospective study was to describe the efficacy of management of bisphosphonate-related maxillary osteonecrosis, which had resulted in an oroantral fistula formation, by performing sequestrectomy, platelet-rich fibrin (PRF) and buccal fat pad (BFP) flap.

Patient and methods: A total of 7 patients diagnosed with stage III maxillary medication-related osteonecrosis according to guidelines of the American Association of Oral and Maxillofacial Surgeons. All patients complained of persistent pain, swelling and purulent drainage with sinusitis. In order to keep the infection under control, the patients first received an antibiotic combination for 2 weeks. Then, sequestrectomy and bone debridement were performed under general anesthesia. After that, an antrectomy was performed via endoscopic sinus surgery in some cases. And the fistula was closed with BFP after or before the PRF application to the region depending on the size of the fistula.

Results: The fistula was successfully closed. After a mean follow-up of 16 months, no symptoms were seen in the patients.

Conclusions: The patients were successfully managed with a combined treatment consisted of sequestrectomy, PRF and BFP. We suggest that large defects arose from medication-related osteonecrosis of the jaw can be managed with such a combined approach in order to lessen the recurrence risk.

Keywords: Bisphosphonates; Buccal fat pad; Medication-related osteonecrosis of the jaw; Oroantral fistula; Platelet-rich fibrin; Sequestrectomy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Intraoral view of the patient revealed that swelling, mucosal ulceration, infection and bone exposure
Fig. 2
Fig. 2
Sequestrotomy and curettage were performed first
Fig. 3
Fig. 3
Centrifuge machine used in the study is seen. (DUO® Quattro Centrifuge)
Fig. 4
Fig. 4
Otained PRFs were placed in the region by forceps and adapted to the cavity with a sponge. Then, the BFP was covered and the region was primarily closed with sutures
Fig. 5
Fig. 5
In cases with insufficient bone cavity, the PRFs were formed into a membrane and adapted to cover the BFP. And then, the mucosa was sutured
Fig. 6
Fig. 6
Buccal fat tissue was extended on the cavity
Fig. 7
Fig. 7
In this case, because the bone cavity was insufficient, PRF was applied as a membrane. The overlying mucosa was sutured over the fat pad tension-free flap closure was achieved
Fig. 8
Fig. 8
No new oroantral communication was observed after an average of 18-month follow-up
See this image and copyright information in PMC

References

    1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Agbaloo T, Mebrotra B, O’Ryan F. American Association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–1956. doi: 10.1016/j.joms.2014.04.031. - DOI - PubMed
    1. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos M. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580–8587. doi: 10.1200/JCO.2005.02.8670. - DOI - PubMed
    1. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–534. doi: 10.1016/j.joms.2004.02.004. - DOI - PubMed
    1. Mast G, Otto S, Mucke T, Schreyer C, Bissinger O, Kolk A, Wolff KD, Ehrenfeld M, Stürzenbaum SR, Pautke C. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2012;40(7):568–571. doi: 10.1016/j.jcms.2011.10.012. - DOI - PubMed
    1. Maurer P, Sandulescu T, Kriwalsky MS, Rashad A, Hollstein S, Stricker I, Hölzle F, Kunkel M. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. Int J Oral Maxillofac Surg. 2011;40(3):285–291. doi: 10.1016/j.ijom.2010.11.006. - DOI - PubMed

LinkOut - more resources